Literature DB >> 18454416

Perioperative visual loss: a rare complication of general surgery.

P-F Kaeser1, F-X Borruat.   

Abstract

BACKGROUND: Perioperative visual loss (PVL) refers to the loss of vision following surgery performed at distance from the visual pathways. An ischemic optic neuropathy (ION) is the most frequent clinical presentation of PVL, and can be bilateral. PATIENTS AND METHODS: A retrospective chart review of 11 consecutive patients with PVL examined between 2002 and 2007 was undertaken.
RESULTS: An ION was found in all 11 cases: 8 were anterior (AION) and 3 were posterior (PION). Visual loss was bilateral in 9 patients. Mean visual acuity (VA) was 0.2 on the Snellen chart (0.74 LogMAR). Most frequently an arcuate/altitudinal visual field defect was present. PVL followed orthopedic (6), spinal (1), cardiac (2) and vascular (2) procedures. The average delay between surgery and visual loss was 32 hours (range: 0-96 hours). Average lowest perioperative hemoglobin level was 75 g/L. Average follow-up time was 14.7 months. VA improved by at least 2 Snellen lines in 5/20 eyes (25 %).
CONCLUSIONS: PVL is a rare but dreadful complication of surgery, and is usually associated with severe anemia. Like other causes of ION, there is no specific therapy. Prompt correction of the anemia might decrease the rate of this complication.

Entities:  

Mesh:

Year:  2008        PMID: 18454416     DOI: 10.1055/s-2008-1027348

Source DB:  PubMed          Journal:  Klin Monbl Augenheilkd        ISSN: 0023-2165            Impact factor:   0.700


  2 in total

1.  [Decreased visual acuity and loss of field of vision after inguinal hernia surgery].

Authors:  B M Stoffelns
Journal:  Ophthalmologe       Date:  2009-05       Impact factor: 1.059

2.  Preoperative Visual Loss is the Main Cause of Irreversible Poor Vision in Children with a Brain Tumor.

Authors:  Nitza Goldenberg-Cohen; Miriam Ehrenberg; Helen Toledano; Liora Kornreich; Moshe Snir; Iftach Yassur; Ian J Cohen; Shalom Michowiz
Journal:  Front Neurol       Date:  2011-09-30       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.